Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00022113 | EMD 121974 in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 35 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2013 | clinicaltrials |
| NCT00022529 | BMS-214662 Plus Trastuzumab in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 28 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2013 | clinicaltrials |
| NCT00039390 |
| Gefitinib and Capecitabine in Treating Patients With Advanced Solid Tumors |
| completed |
| Phase 1 |
| 41 |
| National Cancer Institute (NCI)NIH |
| 1 |
| Jan 25, 2013 |
| clinicaltrials |
| NCT00060112 | Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma | terminated | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2013 | clinicaltrials |
| NCT00079352 | Flavopiridol, Gemcitabine, and Irinotecan in Treating Patients With Unresectable or Metastatic Solid Tumors | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2013 | clinicaltrials |
| NCT00087217 | 17-N-Allylamino-17-Demethoxygeldanamycin and Paclitaxel in Treating Patients With Metastatic or Unresectable Solid Tumor | completed | Phase 1 | 35 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2013 | clinicaltrials |
| NCT00089271 | 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2013 | clinicaltrials |
| NCT00003970 | Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00030693 | Vaccine Therapy in Treating Patients With Metastatic Solid Tumors | terminated | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00042809 | Erlotinib, Trastuzumab, and Paclitaxel in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00049088 | Bortezomib and Docetaxel in Treating Patients With Advanced Solid Tumors | terminated | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00062127 | Irinotecan and Thalidomide in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 35 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00074022 | GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid Tumors | completed | Phase 1 / Phase 2 | 48 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00077155 | Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma | completed | Phase 1 | 45 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00078962 | GTI-2040 and Gemcitabine in Treating Patients With Metastatic or Unresectable Solid Tumors | completed | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00086970 | Ifosfamide With or Without O(6)-Benzylguanine in Treating Patients With Unresectable, Metastatic Solid Tumors | terminated | Phase 1 | 32 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00098891 | MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00005973 | BMS-214662 in Treating Patients With Solid Tumors | completed | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00024206 | SU6668 in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00040781 | Gefitinib in Treating Children With Refractory Solid Tumors | completed | Phase 1 | 45 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00798889 | Rollover Protocol for Prior SU011248 Protocols | completed | N/A | 314 | PfizerINDUSTRY | 11 | Jan 21, 2013 | clinicaltrials |
| NCT00005805 | St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer | completed | Phase 3 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 18, 2013 | clinicaltrials |
| NCT00028561 | BMS-247550 Plus Carboplatin in Treating Patients With Recurrent or Refractory Solid Tumors | terminated | Phase 1 | 45 | National Cancer Institute (NCI)NIH | 1 | Jan 17, 2013 | clinicaltrials |
| NCT00039481 | Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid Tumors | completed | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Jan 17, 2013 | clinicaltrials |
| NCT00084786 | Gefitinib and Docetaxel in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 17, 2013 | clinicaltrials |
| NCT00003282 | EF5 in Treating Patients With Solid Tumors | completed | Phase 1 | 50 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00028587 | PS-341 and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 96 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00028821 | 2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00030498 | Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction | completed | Phase 1 | 75 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00053963 | FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00363272 | Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00101244 | SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma | terminated | Phase 1 | 31 | National Cancer Institute (NCI)NIH | 1 | Jan 14, 2013 | clinicaltrials |
| NCT01472003 | An Evaluation of the Biodistribution and Imaging Characteristics of ABT-806i (111In-ABT-806) in Subjects With Advanced Solid Tumor Types | completed | Phase 1 | 18 | AbbVie (prior sponsor, Abbott)INDUSTRY | 1 | Jan 14, 2013 | clinicaltrials |
| NCT00017238 | KRN5500 in Treating Patients With Solid Tumors | completed | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Jan 11, 2013 | clinicaltrials |
| NCT00026169 | Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney Failure | completed | Phase 1 | 69 | National Cancer Institute (NCI)NIH | 1 | Jan 10, 2013 | clinicaltrials |
| NCT00086983 | Rebeccamycin Analog and Oxaliplatin in Treating Patients With Refractory Solid Tumors | terminated | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Jan 10, 2013 | clinicaltrials |
| NCT00601133 | Function and Balance for Inpatient Rehabilitation | completed | — | 24 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 10, 2013 | clinicaltrials |
| NCT00891072 | Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Jan 10, 2013 | clinicaltrials |
| NCT00047034 | E7389 in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 31 | National Cancer Institute (NCI)NIH | 1 | Jan 7, 2013 | clinicaltrials |
| NCT00089089 | Decitabine in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas | terminated | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Jan 7, 2013 | clinicaltrials |
| NCT00118170 | Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function | completed | Phase 1 | 150 | National Cancer Institute (NCI)NIH | 1 | Jan 7, 2013 | clinicaltrials |
| NCT00124605 | Arsenic Trioxide and Pamidronate in Treating Patients With Advanced Solid Tumors or Multiple Myeloma | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Jan 7, 2013 | clinicaltrials |
| NCT01380249 | PDM08 Clinical Trial in Advanced Solid Tumors | completed | Phase 1 | 22 | Prodimed S.A.OTHER | 1 | Jan 7, 2013 | clinicaltrials |
| NCT01226407 | Examine Maximum Tolerated Dose and Pharmacokinetic and Pharmacodynamic Profile | unknown | Phase 1 | 36 | CrystalGenomics, Inc.INDUSTRY | 1 | Dec 31, 2012 | clinicaltrials |
| NCT00849550 | Safety and Dosage Study of RAD001 (Everolimus) in Combination With Current Standard of Care to Treat Advanced Solid Tumors.(COBRA) | completed | Phase 1 | 32 | Herbert HurwitzOTHER | 1 | Dec 24, 2012 | clinicaltrials |
| NCT01055795 | Safety Study of Bevacizumab, Everolimus and LBH589 (BEL) for Advanced Solid Tumors(BEL) | completed | Phase 1 | 14 | Herbert HurwitzOTHER | 1 | Dec 24, 2012 | clinicaltrials |
| NCT01755390 | A Dose Finding Study of XRP6258 in Patients With Advanced Solid Tumors | completed | Phase 1 | 42 | SanofiINDUSTRY | 2 | Dec 24, 2012 | clinicaltrials |
| NCT01336582 | Pharmacokinetic Study of SYP-0704A and Taxotere to Treat Patient With Advanced Solid Cancer | completed | Phase 1 | 42 | Samyang Biopharmaceuticals CorporationINDUSTRY | 1 | Dec 21, 2012 | clinicaltrials |
| NCT01416623 | A Phase I Study of Henatinib in Patients With Advanced Solid Malignancies | terminated | Phase 1 | 44 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Dec 21, 2012 | clinicaltrials |
Data updated 23 days agoSource updated Jan 25, 2013source: clinicaltrials